nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Gefitinib—lung cancer	0.123	0.32	CbGbCtD
Methylnaltrexone—CYP2D6—Vinorelbine—lung cancer	0.0948	0.246	CbGbCtD
Methylnaltrexone—CYP2D6—Erlotinib—lung cancer	0.0728	0.189	CbGbCtD
Methylnaltrexone—CYP2D6—Vinblastine—lung cancer	0.0584	0.152	CbGbCtD
Methylnaltrexone—Gastrointestinal perforation—Crizotinib—lung cancer	0.048	0.0959	CcSEcCtD
Methylnaltrexone—Gastrointestinal perforation—Gefitinib—lung cancer	0.0436	0.0871	CcSEcCtD
Methylnaltrexone—CYP2D6—Doxorubicin—lung cancer	0.0359	0.0933	CbGbCtD
Methylnaltrexone—Gastrointestinal perforation—Erlotinib—lung cancer	0.026	0.052	CcSEcCtD
Methylnaltrexone—Gastrointestinal perforation—Docetaxel—lung cancer	0.0128	0.0257	CcSEcCtD
Methylnaltrexone—Redness—Paclitaxel—lung cancer	0.00586	0.0117	CcSEcCtD
Methylnaltrexone—Injection site reaction—Vinorelbine—lung cancer	0.00584	0.0117	CcSEcCtD
Methylnaltrexone—Naltrexone—UGT1A1—lung cancer	0.00564	0.38	CrCbGaD
Methylnaltrexone—Erythema—Pemetrexed—lung cancer	0.005	0.01	CcSEcCtD
Methylnaltrexone—Redness—Docetaxel—lung cancer	0.00496	0.00992	CcSEcCtD
Methylnaltrexone—Injection site reaction—Gemcitabine—lung cancer	0.00469	0.00938	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Crizotinib—lung cancer	0.00463	0.00925	CcSEcCtD
Methylnaltrexone—Oedema—Crizotinib—lung cancer	0.00447	0.00893	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Crizotinib—lung cancer	0.00438	0.00875	CcSEcCtD
Methylnaltrexone—Skin disorder—Crizotinib—lung cancer	0.00434	0.00867	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Pemetrexed—lung cancer	0.00423	0.00845	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gefitinib—lung cancer	0.0042	0.0084	CcSEcCtD
Methylnaltrexone—Oedema—Pemetrexed—lung cancer	0.00408	0.00816	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Pemetrexed—lung cancer	0.004	0.008	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gefitinib—lung cancer	0.00398	0.00795	CcSEcCtD
Methylnaltrexone—Skin disorder—Pemetrexed—lung cancer	0.00397	0.00792	CcSEcCtD
Methylnaltrexone—Skin disorder—Gefitinib—lung cancer	0.00394	0.00787	CcSEcCtD
Methylnaltrexone—Injection site reaction—Paclitaxel—lung cancer	0.00393	0.00785	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Crizotinib—lung cancer	0.00386	0.00771	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Pemetrexed—lung cancer	0.00352	0.00704	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gefitinib—lung cancer	0.0035	0.007	CcSEcCtD
Methylnaltrexone—Pain—Pemetrexed—lung cancer	0.00349	0.00698	CcSEcCtD
Methylnaltrexone—Pain—Gefitinib—lung cancer	0.00347	0.00693	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Pemetrexed—lung cancer	0.00334	0.00667	CcSEcCtD
Methylnaltrexone—Injection site reaction—Docetaxel—lung cancer	0.00333	0.00666	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Gefitinib—lung cancer	0.00332	0.00663	CcSEcCtD
Methylnaltrexone—Oedema—Teniposide—lung cancer	0.00331	0.00661	CcSEcCtD
Methylnaltrexone—Abdominal pain—Pemetrexed—lung cancer	0.00323	0.00645	CcSEcCtD
Methylnaltrexone—Abdominal pain—Gefitinib—lung cancer	0.00321	0.00641	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Teniposide—lung cancer	0.0032	0.00639	CcSEcCtD
Methylnaltrexone—Redness—Doxorubicin—lung cancer	0.0031	0.00619	CcSEcCtD
Methylnaltrexone—Diarrhoea—Crizotinib—lung cancer	0.00306	0.00611	CcSEcCtD
Methylnaltrexone—Erythema—Erlotinib—lung cancer	0.00297	0.00594	CcSEcCtD
Methylnaltrexone—Dizziness—Crizotinib—lung cancer	0.00295	0.0059	CcSEcCtD
Methylnaltrexone—Flatulence—Erlotinib—lung cancer	0.00293	0.00585	CcSEcCtD
Methylnaltrexone—Vomiting—Crizotinib—lung cancer	0.00284	0.00568	CcSEcCtD
Methylnaltrexone—Diarrhoea—Pemetrexed—lung cancer	0.00279	0.00558	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gefitinib—lung cancer	0.00278	0.00555	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Teniposide—lung cancer	0.0027	0.0054	CcSEcCtD
Methylnaltrexone—Dizziness—Pemetrexed—lung cancer	0.0027	0.00539	CcSEcCtD
Methylnaltrexone—Nausea—Crizotinib—lung cancer	0.00265	0.0053	CcSEcCtD
Methylnaltrexone—Abdominal pain—Teniposide—lung cancer	0.00261	0.00522	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP2A6—lung cancer	0.00261	0.176	CrCbGaD
Methylnaltrexone—Vomiting—Pemetrexed—lung cancer	0.0026	0.00519	CcSEcCtD
Methylnaltrexone—Stinging—Doxorubicin—lung cancer	0.00258	0.00516	CcSEcCtD
Methylnaltrexone—Vomiting—Gefitinib—lung cancer	0.00258	0.00515	CcSEcCtD
Methylnaltrexone—Erythema—Vinorelbine—lung cancer	0.00257	0.00513	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.00254	0.00507	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.00251	0.00502	CcSEcCtD
Methylnaltrexone—Oedema—Erlotinib—lung cancer	0.00243	0.00485	CcSEcCtD
Methylnaltrexone—Nausea—Pemetrexed—lung cancer	0.00243	0.00485	CcSEcCtD
Methylnaltrexone—Nausea—Gefitinib—lung cancer	0.00241	0.00482	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Topotecan—lung cancer	0.0024	0.0048	CcSEcCtD
Methylnaltrexone—Skin disorder—Topotecan—lung cancer	0.00238	0.00476	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Erlotinib—lung cancer	0.00238	0.00475	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Topotecan—lung cancer	0.00237	0.00474	CcSEcCtD
Methylnaltrexone—Skin disorder—Erlotinib—lung cancer	0.00236	0.00471	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCG2—lung cancer	0.00233	0.157	CrCbGaD
Methylnaltrexone—Diarrhoea—Teniposide—lung cancer	0.00226	0.00452	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00217	0.00434	CcSEcCtD
Methylnaltrexone—Pain—Vinblastine—lung cancer	0.00216	0.00431	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Topotecan—lung cancer	0.00212	0.00423	CcSEcCtD
Methylnaltrexone—Vomiting—Teniposide—lung cancer	0.0021	0.0042	CcSEcCtD
Methylnaltrexone—Pain—Topotecan—lung cancer	0.0021	0.00419	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Erlotinib—lung cancer	0.00209	0.00418	CcSEcCtD
Methylnaltrexone—Flatulence—Irinotecan—lung cancer	0.00209	0.00417	CcSEcCtD
Methylnaltrexone—Injection site reaction—Doxorubicin—lung cancer	0.00208	0.00415	CcSEcCtD
Methylnaltrexone—Pain—Erlotinib—lung cancer	0.00207	0.00414	CcSEcCtD
Methylnaltrexone—Erythema—Gemcitabine—lung cancer	0.00206	0.00412	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vinblastine—lung cancer	0.00206	0.00412	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vinorelbine—lung cancer	0.00206	0.00411	CcSEcCtD
Methylnaltrexone—Skin disorder—Vinorelbine—lung cancer	0.00204	0.00407	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Topotecan—lung cancer	0.002	0.00401	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vinblastine—lung cancer	0.00199	0.00399	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Erlotinib—lung cancer	0.00198	0.00396	CcSEcCtD
Methylnaltrexone—Nausea—Teniposide—lung cancer	0.00196	0.00393	CcSEcCtD
Methylnaltrexone—Abdominal pain—Topotecan—lung cancer	0.00194	0.00387	CcSEcCtD
Methylnaltrexone—Erythema—Cisplatin—lung cancer	0.00192	0.00384	CcSEcCtD
Methylnaltrexone—Abdominal pain—Erlotinib—lung cancer	0.00192	0.00383	CcSEcCtD
Methylnaltrexone—Flatulence—Cisplatin—lung cancer	0.0019	0.00379	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00181	0.00362	CcSEcCtD
Methylnaltrexone—Pain—Vinorelbine—lung cancer	0.00179	0.00358	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.00175	0.00349	CcSEcCtD
Methylnaltrexone—Oedema—Irinotecan—lung cancer	0.00173	0.00346	CcSEcCtD
Methylnaltrexone—Erythema—Paclitaxel—lung cancer	0.00173	0.00345	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vinblastine—lung cancer	0.00173	0.00345	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vinorelbine—lung cancer	0.00171	0.00343	CcSEcCtD
Methylnaltrexone—Flatulence—Paclitaxel—lung cancer	0.0017	0.0034	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Irinotecan—lung cancer	0.0017	0.00339	CcSEcCtD
Methylnaltrexone—Oedema—Gemcitabine—lung cancer	0.00168	0.00337	CcSEcCtD
Methylnaltrexone—Diarrhoea—Topotecan—lung cancer	0.00168	0.00335	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Irinotecan—lung cancer	0.00167	0.00334	CcSEcCtD
Methylnaltrexone—Dizziness—Vinblastine—lung cancer	0.00167	0.00333	CcSEcCtD
Methylnaltrexone—Diarrhoea—Erlotinib—lung cancer	0.00166	0.00332	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vinorelbine—lung cancer	0.00166	0.00331	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gemcitabine—lung cancer	0.00165	0.0033	CcSEcCtD
Methylnaltrexone—Skin disorder—Gemcitabine—lung cancer	0.00164	0.00327	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Gemcitabine—lung cancer	0.00163	0.00325	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.00163	0.00325	CcSEcCtD
Methylnaltrexone—Dizziness—Topotecan—lung cancer	0.00162	0.00324	CcSEcCtD
Methylnaltrexone—Vomiting—Vinblastine—lung cancer	0.0016	0.00321	CcSEcCtD
Methylnaltrexone—Dizziness—Erlotinib—lung cancer	0.0016	0.0032	CcSEcCtD
Methylnaltrexone—Oedema—Cisplatin—lung cancer	0.00157	0.00314	CcSEcCtD
Methylnaltrexone—Vomiting—Topotecan—lung cancer	0.00156	0.00311	CcSEcCtD
Methylnaltrexone—Vomiting—Erlotinib—lung cancer	0.00154	0.00308	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Cisplatin—lung cancer	0.00154	0.00308	CcSEcCtD
Methylnaltrexone—Skin disorder—Cisplatin—lung cancer	0.00153	0.00305	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Cisplatin—lung cancer	0.00152	0.00303	CcSEcCtD
Methylnaltrexone—Nausea—Vinblastine—lung cancer	0.0015	0.00299	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Irinotecan—lung cancer	0.00149	0.00298	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00149	0.00298	CcSEcCtD
Methylnaltrexone—Pain—Irinotecan—lung cancer	0.00148	0.00296	CcSEcCtD
Methylnaltrexone—Erythema—Docetaxel—lung cancer	0.00146	0.00293	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.00146	0.00292	CcSEcCtD
Methylnaltrexone—Nausea—Topotecan—lung cancer	0.00146	0.00291	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00145	0.00291	CcSEcCtD
Methylnaltrexone—Pain—Gemcitabine—lung cancer	0.00144	0.00288	CcSEcCtD
Methylnaltrexone—Nausea—Erlotinib—lung cancer	0.00144	0.00288	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vinorelbine—lung cancer	0.00143	0.00287	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Irinotecan—lung cancer	0.00141	0.00283	CcSEcCtD
Methylnaltrexone—Oedema—Paclitaxel—lung cancer	0.00141	0.00282	CcSEcCtD
Methylnaltrexone—Skin disorder—Etoposide—lung cancer	0.0014	0.00279	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Etoposide—lung cancer	0.00139	0.00278	CcSEcCtD
Methylnaltrexone—Dizziness—Vinorelbine—lung cancer	0.00139	0.00277	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Paclitaxel—lung cancer	0.00138	0.00276	CcSEcCtD
Methylnaltrexone—Skin disorder—Paclitaxel—lung cancer	0.00137	0.00274	CcSEcCtD
Methylnaltrexone—Abdominal pain—Irinotecan—lung cancer	0.00137	0.00273	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Paclitaxel—lung cancer	0.00136	0.00272	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Cisplatin—lung cancer	0.00136	0.00271	CcSEcCtD
Methylnaltrexone—Pain—Cisplatin—lung cancer	0.00134	0.00268	CcSEcCtD
Methylnaltrexone—Vomiting—Vinorelbine—lung cancer	0.00133	0.00266	CcSEcCtD
Methylnaltrexone—Naltrexone—ABCB1—lung cancer	0.00132	0.089	CrCbGaD
Methylnaltrexone—Nausea—Vinorelbine—lung cancer	0.00125	0.00249	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Etoposide—lung cancer	0.00124	0.00248	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.00124	0.00247	CcSEcCtD
Methylnaltrexone—Pain—Etoposide—lung cancer	0.00123	0.00246	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00122	0.00243	CcSEcCtD
Methylnaltrexone—Pain—Paclitaxel—lung cancer	0.00121	0.00241	CcSEcCtD
Methylnaltrexone—Oedema—Docetaxel—lung cancer	0.0012	0.00239	CcSEcCtD
Methylnaltrexone—Diarrhoea—Irinotecan—lung cancer	0.00118	0.00236	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Etoposide—lung cancer	0.00118	0.00235	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Docetaxel—lung cancer	0.00117	0.00234	CcSEcCtD
Methylnaltrexone—Skin disorder—Docetaxel—lung cancer	0.00116	0.00232	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Paclitaxel—lung cancer	0.00115	0.0023	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gemcitabine—lung cancer	0.00115	0.0023	CcSEcCtD
Methylnaltrexone—Dizziness—Irinotecan—lung cancer	0.00114	0.00229	CcSEcCtD
Methylnaltrexone—Abdominal pain—Etoposide—lung cancer	0.00114	0.00227	CcSEcCtD
Methylnaltrexone—Abdominal pain—Paclitaxel—lung cancer	0.00111	0.00223	CcSEcCtD
Methylnaltrexone—Vomiting—Irinotecan—lung cancer	0.0011	0.0022	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cisplatin—lung cancer	0.00107	0.00215	CcSEcCtD
Methylnaltrexone—Vomiting—Gemcitabine—lung cancer	0.00107	0.00214	CcSEcCtD
Methylnaltrexone—Erythema—Methotrexate—lung cancer	0.00106	0.00211	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Docetaxel—lung cancer	0.00103	0.00206	CcSEcCtD
Methylnaltrexone—Nausea—Irinotecan—lung cancer	0.00103	0.00205	CcSEcCtD
Methylnaltrexone—Pain—Docetaxel—lung cancer	0.00102	0.00204	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—lung cancer	0.00101	0.068	CrCbGaD
Methylnaltrexone—Nausea—Gemcitabine—lung cancer	0.001	0.002	CcSEcCtD
Methylnaltrexone—Vomiting—Cisplatin—lung cancer	0.000998	0.00199	CcSEcCtD
Methylnaltrexone—Diarrhoea—Etoposide—lung cancer	0.000984	0.00197	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Docetaxel—lung cancer	0.000978	0.00195	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCB1—lung cancer	0.00097	0.0654	CrCbGaD
Methylnaltrexone—Diarrhoea—Paclitaxel—lung cancer	0.000965	0.00193	CcSEcCtD
Methylnaltrexone—Naloxone—ABCB1—lung cancer	0.000963	0.0649	CrCbGaD
Methylnaltrexone—Dizziness—Etoposide—lung cancer	0.000951	0.0019	CcSEcCtD
Methylnaltrexone—Abdominal pain—Docetaxel—lung cancer	0.000945	0.00189	CcSEcCtD
Methylnaltrexone—Dizziness—Paclitaxel—lung cancer	0.000933	0.00186	CcSEcCtD
Methylnaltrexone—Nausea—Cisplatin—lung cancer	0.000933	0.00186	CcSEcCtD
Methylnaltrexone—Vomiting—Etoposide—lung cancer	0.000915	0.00183	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—lung cancer	0.000914	0.00183	CcSEcCtD
Methylnaltrexone—Flatulence—Doxorubicin—lung cancer	0.000901	0.0018	CcSEcCtD
Methylnaltrexone—Vomiting—Paclitaxel—lung cancer	0.000897	0.00179	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000893	0.00178	CcSEcCtD
Methylnaltrexone—Nausea—Etoposide—lung cancer	0.000854	0.00171	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Methotrexate—lung cancer	0.000845	0.00169	CcSEcCtD
Methylnaltrexone—Nausea—Paclitaxel—lung cancer	0.000838	0.00167	CcSEcCtD
Methylnaltrexone—Skin disorder—Methotrexate—lung cancer	0.000837	0.00167	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methotrexate—lung cancer	0.000833	0.00166	CcSEcCtD
Methylnaltrexone—Diarrhoea—Docetaxel—lung cancer	0.000818	0.00163	CcSEcCtD
Methylnaltrexone—Dizziness—Docetaxel—lung cancer	0.000791	0.00158	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000773	0.00154	CcSEcCtD
Methylnaltrexone—Vomiting—Docetaxel—lung cancer	0.00076	0.00152	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—lung cancer	0.000746	0.00149	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methotrexate—lung cancer	0.000744	0.00149	CcSEcCtD
Methylnaltrexone—Pain—Methotrexate—lung cancer	0.000737	0.00147	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—lung cancer	0.000732	0.00146	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—lung cancer	0.000725	0.00145	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—lung cancer	0.000721	0.00144	CcSEcCtD
Methylnaltrexone—Nausea—Docetaxel—lung cancer	0.00071	0.00142	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methotrexate—lung cancer	0.000705	0.00141	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methotrexate—lung cancer	0.000681	0.00136	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000644	0.00129	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—lung cancer	0.000638	0.00127	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—lung cancer	0.00061	0.00122	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—lung cancer	0.00059	0.00118	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methotrexate—lung cancer	0.00059	0.00118	CcSEcCtD
Methylnaltrexone—Dizziness—Methotrexate—lung cancer	0.00057	0.00114	CcSEcCtD
Methylnaltrexone—Vomiting—Methotrexate—lung cancer	0.000548	0.00109	CcSEcCtD
Methylnaltrexone—Nausea—Methotrexate—lung cancer	0.000512	0.00102	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—lung cancer	0.00051	0.00102	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—lung cancer	0.000493	0.000986	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—lung cancer	0.000474	0.000948	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—lung cancer	0.000443	0.000886	CcSEcCtD
Methylnaltrexone—CYP2D6—Metabolism—AZIN2—lung cancer	0.000119	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DUSP3—lung cancer	0.000118	0.00118	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—APP—lung cancer	0.000118	0.00118	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RHEB—lung cancer	0.000116	0.00116	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ANXA1—lung cancer	0.000113	0.00113	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRM8—lung cancer	0.00011	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PXN—lung cancer	0.000109	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000109	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AVP—lung cancer	0.000108	0.00109	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—POMC—lung cancer	0.000108	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GRP—lung cancer	0.000107	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKR1C1—lung cancer	0.000107	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—OXTR—lung cancer	0.000107	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—APP—lung cancer	0.000107	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SKI—lung cancer	0.000107	0.00107	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ATP5H—lung cancer	0.000101	0.00101	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—POMC—lung cancer	0.000101	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNG11—lung cancer	0.0001	0.001	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL8—lung cancer	9.86e-05	0.000987	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AVP—lung cancer	9.84e-05	0.000985	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFC—lung cancer	9.56e-05	0.000957	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PXN—lung cancer	9.25e-05	0.000926	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AVP—lung cancer	9.16e-05	0.000917	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GRP—lung cancer	9.06e-05	0.000907	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKR1C1—lung cancer	9.06e-05	0.000907	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—OXTR—lung cancer	9.06e-05	0.000907	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLBD1—lung cancer	9.03e-05	0.000904	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADCY1—lung cancer	9.02e-05	0.000903	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PPP2R1B—lung cancer	8.79e-05	0.00088	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SMARCA4—lung cancer	8.79e-05	0.00088	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HSPB1—lung cancer	8.48e-05	0.000849	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNG11—lung cancer	8.48e-05	0.000849	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTHLH—lung cancer	8.39e-05	0.00084	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL8—lung cancer	8.33e-05	0.000834	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AVP—lung cancer	8.32e-05	0.000833	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD17B10—lung cancer	8.26e-05	0.000827	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFC—lung cancer	8.08e-05	0.000809	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ANXA1—lung cancer	7.89e-05	0.00079	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CKB—lung cancer	7.68e-05	0.000768	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FLT1—lung cancer	7.64e-05	0.000765	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADCY1—lung cancer	7.63e-05	0.000764	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CG—lung cancer	7.57e-05	0.000758	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APP—lung cancer	7.48e-05	0.000749	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH3—lung cancer	7.48e-05	0.000749	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SMARCA4—lung cancer	7.43e-05	0.000744	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PPP2R1B—lung cancer	7.43e-05	0.000744	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF9—lung cancer	7.42e-05	0.000742	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM2—lung cancer	7.22e-05	0.000723	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CNDP2—lung cancer	7.22e-05	0.000723	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—POMC—lung cancer	7.2e-05	0.000721	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HSPB1—lung cancer	7.17e-05	0.000718	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTHLH—lung cancer	7.09e-05	0.00071	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JUNB—lung cancer	7.08e-05	0.000709	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTMR3—lung cancer	7.02e-05	0.000703	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—lung cancer	6.87e-05	0.000688	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PGAM1—lung cancer	6.84e-05	0.000685	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ANXA1—lung cancer	6.67e-05	0.000667	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CD—lung cancer	6.65e-05	0.000666	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—POMC—lung cancer	6.54e-05	0.000655	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2A7—lung cancer	6.53e-05	0.000653	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FLT1—lung cancer	6.46e-05	0.000646	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STK11—lung cancer	6.43e-05	0.000644	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—lung cancer	6.4e-05	0.00064	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SDC4—lung cancer	6.39e-05	0.000639	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6R—lung cancer	6.38e-05	0.000639	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APP—lung cancer	6.32e-05	0.000633	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH3—lung cancer	6.32e-05	0.000633	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF9—lung cancer	6.27e-05	0.000627	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FOXO3—lung cancer	6.21e-05	0.000621	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—POMC—lung cancer	6.09e-05	0.00061	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAP2K1—lung cancer	6.08e-05	0.000609	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—lung cancer	6.04e-05	0.000605	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JUNB—lung cancer	5.98e-05	0.000599	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—RRM1—lung cancer	5.82e-05	0.000582	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA3—lung cancer	5.82e-05	0.000582	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AVP—lung cancer	5.82e-05	0.000582	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—lung cancer	5.81e-05	0.000581	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—lung cancer	5.8e-05	0.000581	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—lung cancer	5.62e-05	0.000563	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1R—lung cancer	5.6e-05	0.00056	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—lung cancer	5.57e-05	0.000558	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—POMC—lung cancer	5.53e-05	0.000553	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HES1—lung cancer	5.5e-05	0.000551	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—B4GALT5—lung cancer	5.47e-05	0.000548	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STK11—lung cancer	5.43e-05	0.000544	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—RAF1—lung cancer	5.39e-05	0.00054	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6R—lung cancer	5.39e-05	0.00054	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—lung cancer	5.33e-05	0.000533	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA4—lung cancer	5.32e-05	0.000533	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—lung cancer	5.27e-05	0.000527	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FOXO3—lung cancer	5.24e-05	0.000525	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA2—lung cancer	5.19e-05	0.000519	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAP2K1—lung cancer	5.14e-05	0.000515	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—lung cancer	5.11e-05	0.000511	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—lung cancer	5.06e-05	0.000507	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB3—lung cancer	5.03e-05	0.000503	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA1—lung cancer	5e-05	0.000501	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCC3—lung cancer	4.95e-05	0.000495	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AVP—lung cancer	4.91e-05	0.000492	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—lung cancer	4.9e-05	0.000491	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—lung cancer	4.84e-05	0.000484	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TERT—lung cancer	4.82e-05	0.000482	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKR1C1—lung cancer	4.79e-05	0.00048	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1R—lung cancer	4.73e-05	0.000474	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—lung cancer	4.71e-05	0.000471	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGFR1—lung cancer	4.68e-05	0.000468	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UGT1A1—lung cancer	4.65e-05	0.000466	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HES1—lung cancer	4.65e-05	0.000465	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—lung cancer	4.61e-05	0.000461	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—RAF1—lung cancer	4.56e-05	0.000456	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—lung cancer	4.5e-05	0.000451	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNG11—lung cancer	4.48e-05	0.000449	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—lung cancer	4.45e-05	0.000446	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOA1—lung cancer	4.45e-05	0.000445	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—lung cancer	4.41e-05	0.000441	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—lung cancer	4.28e-05	0.000428	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDOA—lung cancer	4.27e-05	0.000427	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB3—lung cancer	4.25e-05	0.000425	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA3—lung cancer	4.15e-05	0.000415	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—lung cancer	4.09e-05	0.000409	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TERT—lung cancer	4.07e-05	0.000408	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—lung cancer	4.06e-05	0.000406	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APC—lung cancer	4.06e-05	0.000406	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KIT—lung cancer	4.06e-05	0.000406	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—NRAS—lung cancer	4.06e-05	0.000406	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADCY1—lung cancer	4.03e-05	0.000404	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG2—lung cancer	4.03e-05	0.000404	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGF—lung cancer	4.01e-05	0.000402	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ENO2—lung cancer	3.95e-05	0.000396	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HPGDS—lung cancer	3.95e-05	0.000396	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGFR1—lung cancer	3.95e-05	0.000396	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPP2R1B—lung cancer	3.93e-05	0.000393	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—lung cancer	3.89e-05	0.00039	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK3—lung cancer	3.89e-05	0.000389	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—POMC—lung cancer	3.86e-05	0.000387	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTT1—lung cancer	3.84e-05	0.000384	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BRAF—lung cancer	3.82e-05	0.000382	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2A6—lung cancer	3.79e-05	0.00038	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCLC—lung cancer	3.79e-05	0.00038	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6R—lung cancer	3.77e-05	0.000377	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CREBBP—lung cancer	3.76e-05	0.000377	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOA1—lung cancer	3.76e-05	0.000376	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—lung cancer	3.72e-05	0.000373	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—lung cancer	3.7e-05	0.00037	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ENO1—lung cancer	3.59e-05	0.00036	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAP2K1—lung cancer	3.59e-05	0.00036	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—lung cancer	3.57e-05	0.000357	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—lung cancer	3.54e-05	0.000354	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KRAS—lung cancer	3.49e-05	0.00035	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—lung cancer	3.43e-05	0.000343	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KIT—lung cancer	3.43e-05	0.000343	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APC—lung cancer	3.43e-05	0.000343	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—NRAS—lung cancer	3.43e-05	0.000343	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGF—lung cancer	3.39e-05	0.00034	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK3—lung cancer	3.29e-05	0.000329	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—POMC—lung cancer	3.27e-05	0.000327	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BRAF—lung cancer	3.23e-05	0.000323	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2E1—lung cancer	3.22e-05	0.000323	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—lung cancer	3.21e-05	0.000321	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MDM2—lung cancer	3.2e-05	0.00032	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NQO1—lung cancer	3.19e-05	0.000319	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RAF1—lung cancer	3.19e-05	0.000319	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6R—lung cancer	3.19e-05	0.000319	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CREBBP—lung cancer	3.18e-05	0.000318	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB2—lung cancer	3.15e-05	0.000316	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—lung cancer	3.13e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MTOR—lung cancer	3.11e-05	0.000311	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—lung cancer	3.11e-05	0.000311	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAP2K1—lung cancer	3.04e-05	0.000304	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—lung cancer	3.02e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—lung cancer	2.99e-05	0.000299	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—lung cancer	2.99e-05	0.000299	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—HRAS—lung cancer	2.97e-05	0.000297	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KRAS—lung cancer	2.95e-05	0.000296	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—lung cancer	2.89e-05	0.000289	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STK11—lung cancer	2.87e-05	0.000288	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—lung cancer	2.86e-05	0.000286	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—lung cancer	2.86e-05	0.000286	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—lung cancer	2.84e-05	0.000285	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—lung cancer	2.79e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JUN—lung cancer	2.78e-05	0.000278	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—lung cancer	2.71e-05	0.000272	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—lung cancer	2.7e-05	0.000271	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MDM2—lung cancer	2.7e-05	0.000271	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1A—lung cancer	2.69e-05	0.00027	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RAF1—lung cancer	2.69e-05	0.00027	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTEN—lung cancer	2.69e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB2—lung cancer	2.66e-05	0.000267	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTP1—lung cancer	2.66e-05	0.000266	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MTOR—lung cancer	2.63e-05	0.000263	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—lung cancer	2.63e-05	0.000263	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—lung cancer	2.62e-05	0.000263	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAT—lung cancer	2.59e-05	0.000259	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EP300—lung cancer	2.56e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—lung cancer	2.53e-05	0.000253	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCB1—lung cancer	2.52e-05	0.000252	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HRAS—lung cancer	2.51e-05	0.000251	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SRC—lung cancer	2.49e-05	0.00025	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TYMS—lung cancer	2.47e-05	0.000247	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—lung cancer	2.44e-05	0.000245	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—lung cancer	2.44e-05	0.000244	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—lung cancer	2.43e-05	0.000243	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—lung cancer	2.42e-05	0.000242	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—lung cancer	2.41e-05	0.000242	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—lung cancer	2.4e-05	0.000241	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—lung cancer	2.4e-05	0.000241	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NRAS—lung cancer	2.4e-05	0.00024	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—lung cancer	2.35e-05	0.000236	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JUN—lung cancer	2.35e-05	0.000235	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1A1—lung cancer	2.32e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ERCC2—lung cancer	2.3e-05	0.00023	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK3—lung cancer	2.3e-05	0.00023	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—lung cancer	2.29e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1A—lung cancer	2.28e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTEN—lung cancer	2.27e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—lung cancer	2.23e-05	0.000224	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—lung cancer	2.22e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—lung cancer	2.19e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EP300—lung cancer	2.17e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SRC—lung cancer	2.11e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KRAS—lung cancer	2.06e-05	0.000207	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—lung cancer	2.05e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—lung cancer	2.03e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NRAS—lung cancer	2.03e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA1—lung cancer	1.99e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK3—lung cancer	1.94e-05	0.000194	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—lung cancer	1.9e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—lung cancer	1.89e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—lung cancer	1.85e-05	0.000185	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—lung cancer	1.83e-05	0.000184	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—lung cancer	1.81e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HRAS—lung cancer	1.75e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KRAS—lung cancer	1.74e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—POMC—lung cancer	1.73e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CREBBP—lung cancer	1.68e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—lung cancer	1.68e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—lung cancer	1.6e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—lung cancer	1.59e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—lung cancer	1.57e-05	0.000158	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—lung cancer	1.55e-05	0.000155	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—lung cancer	1.55e-05	0.000155	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HRAS—lung cancer	1.48e-05	0.000148	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—lung cancer	1.42e-05	0.000142	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—lung cancer	1.39e-05	0.000139	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—lung cancer	1.38e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—lung cancer	1.31e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTEN—lung cancer	1.2e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—EP300—lung cancer	1.15e-05	0.000115	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—lung cancer	8.47e-06	8.48e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—lung cancer	6.92e-06	6.93e-05	CbGpPWpGaD
